Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

251
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
251

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Amino acids for renal protection: time to implement in clinical practice.

Korean journal of anesthesiology·2026
Same author

Sex-related mortality differences in septic shock: A propensity score-matched study.

Journal of critical care·2026
Same author

Association of duration of amino acids infusion and renal protection: a secondary analysis of the PROTECTION trial.

British journal of anaesthesia·2026
Same author

Neurocognitive outcomes: methodological clarifications.

Anaesthesia·2026
Same author

Acute normovolaemic haemodilution after cardiac surgery: a meta-analysis of randomised controlled trials.

British journal of anaesthesia·2026
Same author

Diabetes does not modify the renal-protective effect of intravenous amino acids infusion after cardiac surgery.

Journal of endocrinological investigation·2026

Related Experiment Video

Updated: Nov 21, 2025

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

9.7K

Esmolol in Cardiac Surgery: A Randomized Controlled Trial.

Alberto Zangrillo1, Elena Bignami2, Beatrice Noè3

  • 1Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Journal of Cardiothoracic and Vascular Anesthesia
|January 16, 2021
PubMed
Summary

Esmolol, an ultra-short-acting beta-blocker, improved cardiac performance after surgery but did not significantly reduce prolonged intensive care unit stays or mortality in cardiac surgery patients.

Keywords:
cardiac surgerycardiopulmonary bypassesmololβ-blockers

More Related Videos

Programmed Electrical Stimulation in Mice
07:29

Programmed Electrical Stimulation in Mice

Published on: May 26, 2010

20.9K
Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.0K

Related Experiment Videos

Last Updated: Nov 21, 2025

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

9.7K
Programmed Electrical Stimulation in Mice
07:29

Programmed Electrical Stimulation in Mice

Published on: May 26, 2010

20.9K
Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.0K

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Pharmacology

Background:

  • Cardiac surgery patients with left ventricular dysfunction are at high risk for adverse postoperative outcomes.
  • Esmolol, an ultra-short-acting beta-blocker, may offer cardioprotective benefits during cardiac surgery.

Purpose of the Study:

  • To evaluate the cardioprotective effect of esmolol as a cardioplegia adjuvant in patients undergoing cardiac surgery.
  • To assess the impact of esmolol on postoperative outcomes, including intensive care unit (ICU) stay and mortality.

Main Methods:

  • A single-center, double-blinded, randomized controlled trial was conducted.
  • Patients with left ventricular end-diastolic diameter >60 mm or ejection fraction <50% undergoing elective cardiac surgery were included.
  • Participants received either esmolol or placebo mixed with cardioplegia solution.

Main Results:

  • The primary composite endpoint (prolonged ICU stay and/or in-hospital mortality) did not significantly differ between groups (36% vs. 27%, p=0.13).
  • Esmolol administration led to a significant reduction in the maximum inotropic score during the first 24 postoperative hours (p=0.04).
  • Trends toward reduced low-cardiac-output syndrome and one-year hospital readmission were observed with esmolol.

Conclusions:

  • Esmolol as a cardioplegia adjuvant enhanced postoperative cardiac performance in the studied cohort.
  • The study did not demonstrate a significant reduction in the composite endpoint of prolonged ICU stay or mortality with esmolol use.
  • Further research may be warranted to explore the specific benefits of esmolol in cardiac surgery.